

# Curriculum Vitae

## Informazioni personali

Cognome Nome **ASTEGIANO MARCO**  
Indirizzo *Piazza Gran Madre di Dio 14 – 10131 - Torino*  
Telefono *+39 3356348383*  
Fax  
E-mail *marcoastegiano58@gmail.com*

Cittadinanza *italiana*  
Data di nascita *30/11/58*

## Esperienza professionale

*Assunzione in qualità di assistente nella Divisione di Gastroenterologia diretta dal Prof. G. Verme il 27/04/1989 a tempo indeterminato*

*Responsabile Poliambulatori e Ambulatorio Diagnosi e Cura delle Malattie dell'Intestino fino al 11/2022*

*Ex Responsabile S.S.C.V.D. Diagnosi e Cura delle Malattie dell'Intestino (CHIUSA) – Città della Salute e della Scienza di Torino – presidio San Giovanni Antica Sede Pensione da 4/12/2022*

<p><b>Principali attività e responsabilità</b></p>	<ul style="list-style-type: none"> <li>❑ <i>Attività di didattica e formazione svolta nei confronti di medici specializzandi e frequentatori, in ambito di assistenza clinica, e di ricerca scientifica (elaborazione lavori scientifici, trials clinici, progetti di ricerca)</i></li> <li>❑ <i>Attività didattica nel corso di specialità di gastroenterologia (insegnamento esami e preparazione tesi di laurea e specialità)</i></li> <li>❑ <i>Attività didattica integrata all'interno del corso di laurea in medicina e chirurgia (ADI)</i></li> <li>❑ <i>Corsi formativi per medici di medicina generale</i></li> <li>❑ <i>Partecipazione a congressi in qualità di relatore e coordinatore</i></li> <li>❑ <i>Responsabile Scientifico Scuola Microbioma Torino</i></li> <li>❑ <i>Espletamento delle attività istituzionali proprie della Struttura Complessa in esecuzione delle direttive formalmente impartite dal Direttore di Struttura Complessa;</i></li> <li>❑ <i>Gestione e coordinamento dell'attività ambulatoriale gastroenterologica ed epatologica</i></li> <li>❑ <i>Gestione della diagnosi e cura delle malattie dell'intestino</i></li> <li>❑ <i>Litotripsia</i></li> <li>❑ <i>Ricerca clinica, impostazione di protocolli diagnostico-terapeutici all'interno della struttura e integrati con il territorio</i></li> <li>❑ <i>Nuove metodologie diagnostico-terapeutiche</i></li> <li>❑ <i>Riunioni periodiche con personale medico-infermieristico-amministrativo.</i></li> <li>❑ <i>Istituzione centro breath test (urea breath test, svuotamento gastrico, test all'aminopirina)</i></li> <li>❑ <i>Procedure per istituzione breath test per intolleranza al lattosio e polluzione batterica</i></li> <li>❑ <i>Istituzione e validazione terapia con leucocitoferesi coinvolgendo Banca del Sangue, Reumatologia, Virologia e Laboratorio di fisiopatologia renale e vascolare dell'ospedale Molinette e laboratorio di Patologia generale ospedale San Luigi</i></li> <li>❑ <i>Partecipazione al registro italiano leucocitoferesi nelle IBD</i></li> <li>❑ <i>Membro del comitato scientifico onlus IBD</i></li> <li>❑ <i>Responsabile del progetto della cartella computerizzata per la gestione dei pazienti con IBD</i></li> </ul>
<p><b>Datore di lavoro</b></p>	<p><i>Azienda ospedaliero-universitaria San Giovanni Battista Torino</i></p>
<p><b>Istruzione e formazione</b></p>	<p><i>Maturità classica nel 1977</i>  <i>Laureato il 01/03/1984 presso l'Università degli Studi di Torino</i>  <i>Abilitato nella I sessione del 1984</i>  <i>Diploma di Specialità in Malattie dell'apparato digerente il 03/11/1989</i>  <i>Frequenza all'estero presso Radcliff Hospital di Oxford dal 10-90 al 2-91</i></p>
<p><b>Principali tematiche/competenze professionali possedute</b></p>	<ul style="list-style-type: none"> <li>❑ <i>sviluppo di percorsi diagnostici/terapeutici/assistenziali e per linee guida su:</i> <ul style="list-style-type: none"> <li>• <i>malattia celiaca</i></li> <li>• <i>diarrea</i></li> <li>• <i>stipsi</i></li> <li>• <i>malattie infiammatorie croniche intestinali</i></li> <li>• <i>terapia con farmaci biologici nelle IBD</i></li> <li>• <i>sindromi funzionali gastrointestinali</i></li> <li>• <i>malattie rare in gastroenterologia (coliti microscopiche, malattia di Whipple, gastroenterite eosinofila, displasia neuronale intestinale, malattia di Hirschprung, sindrome di Ehler-Danlos, acalasia, malattia di Behcet)</i></li> </ul> </li> </ul>

**Capacità e competenze personali**

**Campi qualificanti sul piano scientifico assistenziale**

*Malattie infiammatorie croniche dell'intestino*  
*Malattia celiaca*  
*Sindromi funzionali intestinali*  
*Malattie rare intestinali*  
*Breath test*  
*ESWL colelitiasi litiasi vie biliari*

Madrelingua

**ITALIANO**

Altre lingue  
Autovalutazione  
Livello europeo (\*)  
**Francese**  
**Inglese**

**Francese-Inglese**

<b>Comprensione</b>		<b>Parlato</b>		<b>Scritto</b>
<i>Ascolto</i>	<i>Lettura</i>	<i>Interazione orale</i>	<i>Produzione orale</i>	
<i>BUONA</i>	<i>BUONA</i>	<i>BUONA</i>	<i>BUONA</i>	<i>BUONA</i>
<i>BUONA</i>	<i>BUONA</i>	<i>OTTIMA</i>	<i>OTTIMA</i>	<i>OTTIMA</i>

(\*) Quadro comune europeo di riferimento per le lingue

**Altre capacità e competenze**

**Breve curriculum didattico**

***Insegnamento area D, Endoscopia Digestiva III-IV anno Scuola di Specializzazione in Gastroenterologia dall'anno 2001-2002 ad oggi.***

***Collaborazione a stesura tesi di laurea in medicina e chirurgia: 3/anno.***

***Collaborazione a stesura tesi di specialità in malattie dell'apparato digerente: 3/anno.***

***ADI per studenti al III anno del Corso di Laurea in Medicina e Chirurgia dal 2001-2002 ad oggi.***

***Insegnamento scuola di specializzazione in Medicina Generale dal 2009 a oggi.***

***Attività didattica di insegnamento per Corso di formazione in Medicina Generale, settore Gastroenterologia dal 2003-2004.***

***Attività didattica di tipo tutoriale nei corsi di formazione specifica in medicina generale 2003-2004 ad oggi.***

***Attività didattica di tipo tutoriale per studenti per Esame di Stato***

## **Ulteriori informazioni**

### ***Partecipazione a progetti nazionali***

*Consensus conference sui breath test all'idrogeno (gruppo di lavoro sul lattosio BT: stesura linee guida nazionali su H2 Breath test e lavoro scientifico inviato per pubblicazione) (2009)*

*Consensus conference Gruppo IBD IC sull'uso degli steroidi e immunosoppressori nella terapia delle IBD (Bologna marzo aprile 2011)*

### ***Partecipazione a progetti regionali***

- *partecipazione alla stesura di un documento per definire la priorità delle visite gastroenterologiche presso assessorato alla sanità regionale (2009)*
- *coordinatore del gruppo sulle malattie infiammatorie croniche dell'intestino (progetto A.Re.S.S. PDTA IBD) (2009-10)*
- *partecipazione al progetto reazione avverse agli alimenti (progetto A.Re.S.S. PDTA) (2010-11)*
- *partecipazione al progetto formativo A.Re.S.S.: il paziente affetto da malattia dell'apparato digerente: i PDTA e i PIC come base della rete regionale di Gastroenterologia (22 giugno 2008, 18 settembre 2008, 22 ottobre 2008). Il corso è stato articolato in tre moduli teorici e due giornate di tirocinio per un totale di 30 ore) (2010)*

**Allegati** | Enumerare gli allegati al CV. (facoltativo, v. istruzioni)

## **PUBBLICAZIONI**

1. Bergamaschi G, Castiglione F, D'Incà R, Astegiano M, Fries W, Milla M, Ciacci C, Rizzello F, Saibeni S, Ciccocioppo R, Orlando A, Bossa F, Principi M, Vernia P, Ricci C, Scribano ML, Bodini G, Mazzucco D, Bassotti G, Riegler G, Buda A, Neri M, Caprioli F, Monica F, Manca A, Villa E, Fiorino G, Comberlato M, Aronico, N, Della Corte C, Caccaro R, Gionchetti P, Giuffrida P, Iovino P, Lenti MV, Mengoli C, Pellegrini L, Pieraccini A, Ribaldone D, Testa A, Ubezio C, Viola A, Vecchi M, Klersy C, Di Sabatino A. Prevalence, Pathogenesis and Management of Anemia in Inflammatory Bowel Disease: An IG-IBD Multicenter, Prospective, and Observational Study. *Inflamm Bowel Dis*. 2022 Apr 2;izac054. doi:10.1093/ibd/izac054. Epub ahead of print. PMID: 35366312.
2. Lavorini E, Allaix ME, Ammirati CA, Astegiano M, Morino M, Resegotti A. Late is too late? Surgical timing and postoperative complications after primary ileocolic resection for Crohn's disease. *Int J Colorectal Dis*. 2022 Apr;37(4):843-848. doi: 10.1007/s00384-022-04125-7. Epub 2022 Mar 10. PMID: 35274184; PMCID: PMC8976788.

3. Stalla FM, Astegiano M, Ribaldone DG, Saracco GM, Pellicano R. The small intestine: barrier, permeability and microbiota. *Minerva Gastroenterol (Torino)*. 2022 Mar;68(1):98-110. doi: 10.23736/S2724-5985.20.02808-1. Epub 2020 Dec 3. PMID: 33267569.
4. Cusato J, Bertani L, Antonucci M, Tomasello C, Caviglia GP, Dibitetto S, Massano A, Mangia M, Mula J, Ceccarelli L, Costa F, Zanzi F, Astegiano M, Ribaldone DG, D'Avolio A. Vitamin D-Related Genetics as Predictive Biomarker of Clinical Remission in Adalimumab-Treated Patients Affected by Crohn's Disease: A Pilot Study. *Pharmaceuticals (Basel)*. 2021 Nov 27;14(12):1230. doi: 10.3390/ph14121230. PMID: 34959633; PMCID: PMC8706953.
5. Caviglia GP, De Blasio F, Venero M, Armandi A, Rosso C, Saracco GM, Bugianesi E, Astegiano M, Ribaldone DG. Efficacy of a Preparation Based on Calcium Butyrate, *Bifidobacterium bifidum*, *Bifidobacterium lactis*, and Fructooligosaccharides in the Prevention of Relapse in Ulcerative Colitis: A Prospective Observational Study. *J Clin Med*. 2021 Oct 26;10(21):4961. doi: 10.3390/jcm10214961. PMID: 34768480; PMCID: PMC8585056.
6. Tursi A, Brandimarte G, Di Mario F, Elisei W, Picchio M, Allegretta L, Annunziata ML, Bafutto M, Bassotti G, Bianco MA, Colucci R, Conigliaro R, Dumitrascu D, Escalante R, Ferrini L, Forti G, Franceschi M, Graziani MG, Lammert F, Latella G, Maconi G, Nardone G, Camara de Castro Oliveira L, Chaves Oliveira E, Papa A, Papagrigroriadis S, Pietrzak A, Pontone S, Poskus T, Pranzo G, Reichert MC, Rodinò S, Regula J, Scaccianoce G, Scaldaferrì F, Vassallo R, Zampalèta C, Zullo A, Piovani D, Bonovas S, Danese S; DICA International Group. Prognostic performance of the 'DICA' endoscopic classification and the 'CODA' score in predicting clinical outcomes of diverticular disease: an international, multicentre, prospective cohort study. *Gut*. 2021 Oct 26;gutjnl-2021-325574. Doi: 10.1136/gutjnl-2021-325574. Epub ahead of print. PMID: 34702716.
7. Ditto MC, Parisi S, Landolfi G, Borrelli R, Realmuto C, Finucci A, Caviglia GP, Ribaldone DG, Astegiano M, Zanetti A, Carrara G, Scirè CA, Antivalle M, Sarzi-Puttini P, Fusaro E. Intestinal microbiota changes induced by TNF- inhibitors in IBD-related spondyloarthritis. *RMD Open*. 2021 Sep;7(3):e001755. doi: 10.1136/rmdopen-2021-001755. PMID: 34489323; PMCID: PMC8422478.
8. Ribaldone DG, Tribocco E, Rosso C, Armandi A, Venero M, Bugianesi E, Astegiano M, Saracco GM, Caviglia GP. Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohn's Disease: A Prospective Study. *J Clin Med*. 2021 Jul 30;10(15):3387. doi: 10.3390/jcm10153387. PMID: 34362184; PMCID: PMC8348781.
9. Caviglia GP, Martini G, Armandi A, Rosso C, Venero M, Bugianesi E, Astegiano M, Saracco GM, Ribaldone DG. Risk Factors of Urothelial Cancer in Inflammatory Bowel Disease. *J Clin Med*. 2021 Jul 23;10(15):3257. doi: 10.3390/jcm10153257. PMID: 34362041; PMCID: PMC8347965.
10. Ribaldone DG, Imperatore N, Le Grazie M, Furfaro F, Balestrieri P, De Blasio F, Fagoonee S, Mosso E, Boano V, Reggio D, Sarli E, Castiglione F, Milla M, Vecchi M, Saracco GM, Salizzoni M, Romagnoli R, Fiorino G, Astegiano M; Italian Group for the study of Inflammatory Bowel Disease IG-IBD. Inflammatory bowel disease course in liver transplant versus non-liver transplant patients for primary sclerosing cholangitis: LIVIBD, an IG-IBD study. *Dig Liver Dis*. 2021 Jun;53(6):712-716. doi: 10.1016/j.dld.2020.09.011. Epub 2020 Sep 21. PMID: 32972831.
11. Ponzo V, Ferrocino I, Goitre I, Pellegrini M, Bruno M, Astegiano M, Cadario G, Castellana E, Bioletto F, Corvaglia MR, Malfa P, Cocolin L, Ghigo E, Bo S. Non-Celiac Gluten/Wheat Sensitivity: Clinical Characteristics and Microbiota and Mycobiota Composition by Response to the Gluten Challenge Test. *Nutrients*. 2021 Apr 12;13(4):1260. doi: 10.3390/nu13041260. PMID: 33921293; PMCID: PMC8070191.
12. Rosso C, Aaron AA, Armandi A, Caviglia GP, Venero M, Saracco GM, Astegiano M, Bugianesi E, Ribaldone DG. Inflammatory Bowel Disease Nurse-Practical Messages. *Nurs Rep*. 2021 Apr 1;11(2):229-241. doi: 10.3390/nursrep11020023. PMID: 34968201; PMCID: PMC8608068.
13. Ribaldone DG, Venero M, Astegiano M. Effectiveness and safety of switching to adalimumab biosimilar ABP 501 in Crohn's disease: the extrapolation concept. *Rev Esp Enferm Dig*. 2021 Feb;113(2):155. doi: 10.17235/reed.2020.7253/2020. PMID: 33207912.
14. Ribaldone DG, Rajesh P, Chandradhara D, Astegiano M, Pellicano R. A randomized, double-blind, placebo-controlled pilot study to evaluate the efficacy and tolerability of a novel oral bioadhesive formulation for the treatment of nonerosive reflux disease-related symptoms. *Eur J Gastroenterol Hepatol*. 2021 Feb 1;32(2):163-170. doi: 10.1097/MEG.0000000000001888. PMID: 32804843.
15. Venero M, De Blasio F, Ribaldone DG, Bugianesi E, Pellicano R, Saracco GM, Astegiano M, Caviglia GP. The Usefulness of Microencapsulated Sodium Butyrate Add-On Therapy in Maintaining Remission in Patients with Ulcerative Colitis: A Prospective Observational Study. *J Clin Med*. 2020 Dec 4;9(12):3941. doi: 10.3390/jcm9123941. PMID: 33291846; PMCID: PMC7762036.

16. Suriani R, Ercole E, Niola P, Astegiano M, Sambataro A, Ravizza M. IBD passport: A novel educational model in IBD patients. *Dig Liver Dis.* 2020 Sep;52(9):1067-1068. doi: 10.1016/j.dld.2020.05.012. Epub 2020 Jun 7. PMID: 32522432.
17. Ribaldone DG, Astegiano M, Actis GC, Pellicano R. Management of inflammatory bowel disease during COVID-19 pandemic. *Minerva Gastroenterol Dietol.* 2020 Sep;66(3):184-186. doi: 10.23736/S1121-421X.20.02707-5. Epub 2020 Apr 23. PMID: 32327626.
18. Rizza S, Mistrangelo M, Ribaldone DG, Morino M, Astegiano M, Saracco GM, Pellicano R. Proctitis: a glance beyond inflammatory bowel diseases. *Minerva Gastroenterol Dietol.* 2020 Sep;66(3):252-266. Doi: 10.23736/S1121-421X.20.02670-7. Epub 2020 Mar 24. PMID: 32218425.
19. Caviglia GP, Tucci A, Pellicano R, Fagoonee S, Rosso C, Abate ML, Olivero A, Armandi A, Vanni E, Saracco GM, Bugianesi E, Astegiano M, Ribaldone DG. Clinical Response and Changes of Cytokines and Zonulin Levels in Patients with Diarrhoea-Predominant Irritable Bowel Syndrome Treated with *Bifidobacterium Longum* ES1 for 8 or 12 Weeks: A Preliminary Report. *J Clin Med.* 2020 Jul 23;9(8):2353. doi: 10.3390/jcm9082353. PMID: 32717980; PMCID: PMC7464152.
20. Giuffrida P, Arpa G, Grillo F, Klersy C, Sampietro G, Ardizzone S, Fociani P, Fiocca R, Latella G, Sessa F, D'Errico A, Malvi D, Mescoli C, Rugge M, Nesi G, Ferrero S, Furlan D, Poggioli G, Rizzello F, Macciomei MC, Santini D, Volta U, De Giorgio R, Caio G, Calabrò A, Ciacci C, D'Armiento M, Rizzo A, Solina G, Martino M, Tonelli F, Villanacci V, Cannizzaro R, Canzonieri V, Florena AM, Biancone L, Monteleone G, Caronna R, Ciardi A, Elli L, Caprioli F, Vecchi M, D'Inca R, Zingone F, D'Odorico A, Lenti MV, Oreggia B, Bonetti LR, Astegiano M, Biletta E, Cantoro L, Giannone AG, Orlandi A, Papi C, Perfetti V, Quaquerini E, Sandri G, Silano M, Usai P, Barresi V, Ciccocioppo R, Luinetti O, Pedrazzoli P, Pietrabissa A, Viglio A, Paulli M, Corazza GR, Solcia E, Vanoli A, Di Sabatino A. Correction: PD-L1 in small bowel adenocarcinoma is associated with etiology and tumor-infiltrating lymphocytes, in addition to microsatellite instability. *Mod Pathol.* 2020 Jul;33(7):1453. doi: 10.1038/s41379-020-0512-5. Erratum for: *Mod Pathol.* 2020 Jul;33(7):1398-1409. PMID: 32132662.
21. Giuffrida P, Arpa G, Grillo F, Klersy C, Sampietro G, Ardizzone S, Fociani P, Fiocca R, Latella G, Sessa F, D'Errico A, Malvi D, Mescoli C, Rugge M, Nesi G, Ferrero S, Furlan D, Poggioli G, Rizzello F, Macciomei MC, Santini D, Volta U, De Giorgio R, Caio G, Calabrò A, Ciacci C, D'Armiento M, Rizzo A, Solina G, Martino M, Tonelli F, Villanacci V, Cannizzaro R, Canzonieri V, Florena AM, Biancone L, Monteleone G, Caronna R, Ciardi A, Elli L, Caprioli F, Vecchi M, D'Inca R, Zingone F, D'Odorico A, Lenti MV, Oreggia B, Reggiani Bonetti L, Astegiano M, Biletta E, Cantoro L, Giannone AG, Orlandi A, Papi C, Perfetti V, Quaquerini E, Sandri G, Silano M, Usai P, Barresi V, Ciccocioppo R, Luinetti O, Pedrazzoli P, Pietrabissa A, Viglio A, Paulli M, Corazza GR, Solcia E, Vanoli A, Di Sabatino A. PD-L1 in small bowel adenocarcinoma is associated with etiology and tumor-infiltrating lymphocytes, in addition to microsatellite instability. *Mod Pathol.* 2020 Jul;33(7):1398-1409. doi: 10.1038/s41379-020-0497-0. Epub 2020 Feb 17. Erratum in: *Mod Pathol.* 2020 Mar 4;: PMID: 32066859.
22. Ribaldone DG, Brigo S, Mangia M, Saracco GM, Astegiano M, Pellicano R. Oral Manifestations of Inflammatory Bowel Disease and the Role of Non-Invasive Surrogate Markers of Disease Activity. *Medicines (Basel).* 2020 Jun 16;7(6):33. doi: 10.3390/medicines7060033. PMID: 32560118; PMCID: PMC7345678.
23. Carli E, Caviglia GP, Pellicano R, Fagoonee S, Rizza S, Astegiano M, Saracco GM, Ribaldone DG. Incidence of Prostate Cancer in Inflammatory Bowel Disease: A Meta-Analysis. *Medicina (Kaunas).* 2020 Jun 11;56(6):285. doi: 10.3390/medicina56060285. PMID: 32545154; PMCID: PMC7353864.
24. Vernero M, Di Leo I, Givone M, Adriani A, Bergamaschi A, Fanelli M, Astegiano M. Role of Compositum Zeolite® in management of inflammatory bowel disease: a pilot study. *Minerva Gastroenterol Dietol.* 2020 Jun;66(2):113-116. doi: 10.23736/S1121-421X.20.02682-3. PMID: 32518220.
25. Vernero M, Ribaldone DG, Cariti C, Ribero S, Susca S, Astegiano M, Dapavo P. Dual-targeted therapy with apremilast and vedolizumab in pyoderma gangrenosum associated with Crohn's disease. *J Dermatol.* 2020 Jun;47(6):e216-e217. Doi: 10.1111/1346-8138.15283. Epub 2020 Apr 29. PMID: 32347562.
26. Ribaldone DG, Procopio M, Pellicano R, Barale M, Giudici G, Morino M, Saracco GM, Astegiano M. Predictors of risk of fracture in inflammatory bowel diseases: a prospective study using FRAX score. *Minerva Gastroenterol Dietol.* 2020 Jun;66(2):106-112. doi: 10.23736/S1121-421X.20.02672-0. Epub 2020 Mar 24. PMID: 32218426.
27. Giudici G, Ribaldone DG, Astegiano M, Saracco GM, Pellicano R. Eosinophilic colitis: clinical review and 2020 update. *Minerva Gastroenterol Dietol.* 2020 Jun;66(2):157-163. doi: 10.23736/S1121-421X.20.02656-2. Epub 2020 Jan 28. PMID: 31994372.
28. Vernero M, Ribaldone DG, Astegiano M, Pellicano R. Risk of incident melanoma in patients with inflammatory disease treated with anti-TNF: the Turin experience. *G Ital Dermatol Venereol.* 2020 Jun;155(3):366-367. doi: 10.23736/S0392-0488.18.06017-0. Epub 2018 Sep 20. PMID: 30249085.

29. Eliadou E, Moleiro J, Ribaldone DG, Astegiano M, Rothfuss K, Taxonera C, Ghalim F, Carbonnel F, Verstockt B, Festa S, Maia L, Berrozpe A, Zagorowicz E, Savarino E, Ellul P, Vavricka SR, Calvo M, Koutroubakis I, Hoentjen F, Salazar LF, Callela F, Cañete Pizarro F, Soufleris K, Sonnenberg E, Cavicchi M, Wypych J, Hommel C, Ghiani A, Fiorino G; ECCO CONFER COMMITTEE. Interstitial and Granulomatous Lung Disease in Inflammatory Bowel Disease Patients. *J Crohns Colitis*. 2020 May 21;14(4):480-489. doi: 10.1093/ecco-jcc/jjz165. PMID:31602473.
30. Bertani L, Caviglia GP, Antonioli L, Pellicano R, Fagoonee S, Astegiano M, Saracco GM, Bugianesi E, Blandizzi C, Costa F, Ribaldone DG. Serum Interleukin-6 and -8 as Predictors of Response to Vedolizumab in Inflammatory Bowel Diseases. *J Clin Med*. 2020 May 2;9(5):1323. doi: 10.3390/jcm9051323. PMID: 32370274; PMCID: PMC7290461.
31. Caviglia GP, Rosso C, Stalla F, Rizzo M, Massano A, Abate ML, Olivero A, Armandi A, Vanni E, Younes R, Fagoonee S, Pellicano R, Astegiano M, Saracco GM, Bugianesi E, Ribaldone DG. On-Treatment Decrease of Serum Interleukin-6 as a Predictor of Clinical Response to Biologic Therapy in Patients with Inflammatory Bowel Diseases. *J Clin Med*. 2020 Mar 15;9(3):800. doi: 10.3390/jcm9030800. PMID: 32183476; PMCID: PMC7141255.
32. Ribaldone DG, Caviglia GP, Pellicano R, Vernero M, Saracco GM, Morino M, Astegiano M. Effectiveness and safety of adalimumab biosimilar ABP 501 in Crohn's disease: an observational study. *Rev Esp Enferm Dig*. 2020 Mar;112(3):195-200. Doi: 10.17235/reed.2020.6693/2019. PMID: 32054272.
33. Ribaldone DG, Pellicano R, Saracco GM, Morino M, Astegiano M. Vedolizumab for treatment of chronic refractory pouchitis: a systematic review with pool analysis. *Rev Esp Enferm Dig*. 2020 Jan;112(1):59-63. Doi: 10.17235/reed.2019.6336/2019. PMID: 31823641.
34. Ribaldone DG, Resegotti A, Astegiano M. The therapy of chronic pouchitis. *Minerva Gastroenterol Dietol*. 2019 Dec;65(4):265-267. Doi:10.23736/S1121-421X.18.02551-5. Epub 2019 Jan 4. PMID: 30623632.
35. Ribaldone DG, Caviglia GP, Pellicano R, Vernero M, Italia A, Morino M, Saracco GM, Astegiano M. Adalimumab versus azathioprine to halt the progression of bowel damage in Crohn's disease: application of Lémann Index. *Scand J Gastroenterol*. 2019 Nov;54(11):1339-1345. Doi: 10.1080/00365521.2019.1686057. Epub 2019 Nov 6. PMID: 31692395.
36. Ribaldone DG, Caviglia GP, Abdulle A, Pellicano R, Ditto MC, Morino M, Fusaro E, Saracco GM, Bugianesi E, Astegiano M. Adalimumab Therapy Improves Intestinal Dysbiosis in Crohn's Disease. *J Clin Med*. 2019 Oct 9;8(10):1646. doi: 10.3390/jcm8101646. PMID: 31601034; PMCID: PMC6832711.
37. Ribaldone DG, Vernero M, Parisi S, Ditto MC, Pellicano R, Morino M, Saracco GM, Fusaro E, Astegiano M. Risk factors of suspected spondyloarthritis among inflammatory bowel disease patients. *Scand J Gastroenterol*. 2019 Oct;54(10):1233-1236. doi: 10.1080/00365521.2019.1668052. Epub 2019 Sep 24. PMID: 31549896.
38. Vernero M, Boano V, Ribaldone DG, Pellicano R, Astegiano M. Oral iron supplementation with Feralgine® in inflammatory bowel disease: a retrospective observational study. *Minerva Gastroenterol Dietol*. 2019 Sep;65(3):200-203. Doi: 10.23736/S1121-421X.19.02572-8. Epub 2019 Mar 27. PMID: 30917629.
39. Ribaldone DG, Adriani A, Caviglia GP, Nicolò A, Agnesod D, Simiele M, Riganò D, Pellicano R, Canaparo R, Perri GD, D'Avolio A, Lizza F, Saracco GM, Astegiano M. Correlation between Thiopurine S-Methyltransferase Genotype and Adverse Events in Inflammatory Bowel Disease Patients. *Medicina (Kaunas)*. 2019 Aug 5;55(8):441. doi: 10.3390/medicina55080441. PMID: 31387318; PMCID: PMC6723288.
40. Ribaldone DG, Resegotti A, Pellicano R, Astegiano M, Saracco GM, Morino M. The role of topical therapy for perianal fistulizing Crohn's disease: are we forgetting something? *Minerva Gastroenterol Dietol*. 2019 Jun;65(2):130-135. Doi: 10.23736/S1121-421X.19.02565-0. Epub 2019 Feb 12. PMID: 30759975.
41. Fiorino G, Caprioli F, Daperno M, Mocciaro F, Principi M, Viscido A, Fantini MC, Orlando A, Papi C, Annese V, Danese S, Vecchi M, Rizzello F, Armuzzi A; National patients' association representatives. Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). *Dig Liver Dis*. 2019 May;51(5):632-639. Doi: 10.1016/j.dld.2019.02.004. Epub 2019 Feb 19. PMID: 30872085.
42. Ribaldone DG, Pellicano R, Vernero M, Caviglia GP, Saracco GM, Morino M, Astegiano M. Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease: a systematic review with pool analysis. *Scand J Gastroenterol*. 2019 Apr;54(4):407-413. doi: 10.1080/00365521.2019.1597159. Epub 2019 Apr 4. PMID: 30945576.
43. Caviglia GP, Dughera F, Ribaldone DG, Rosso C, Abate ML, Pellicano R, Bresso F, Smedile A, Saracco GM, Astegiano M. Serum zonulin in patients with inflammatory bowel disease: a pilot study. *Minerva Med*. 2019 Apr;110(2):95-100. doi: 10.23736/S0026-4806.18.05787-7. Epub 2018 Aug 28. PMID: 30160088.



44. Manfredi M, Conte E, Barberis E, Buzzi A, Robotti E, Caneparo V, Cecconi D, Brandi J, Vanni E, Finocchiaro M, Astegiano M, Gariglio M, Marengo E, De Andrea M. Integrated serum proteins and fatty acids analysis for putative biomarker discovery in inflammatory bowel disease. *J Proteomics*. 2019 Mar 20;195:138-149. doi: 10.1016/j.jprot.2018.10.017. Epub 2018 Nov 2. PMID: 30391485.
45. Tursi A, Brandimarte G, di Mario F, Nardone G, Scarpignato C, Picchio M, Elisei W; DICA Italian Group. The "DICA" endoscopic classification for diverticular disease of the colon shows a significant interobserver agreement among community endoscopists. *J Gastrointest Liver Dis*. 2019 Mar;28(1):23-27. doi: 10.15403/jgld.2014.1121.281.dic. PMID: 30851168.
46. Ribaldone DG, Fagoonee S, Astegiano M, Durazzo M, Morgando A, Sprujevnik T, Giordanino C, Baronio M, De Angelis C, Saracco GM, Pellicano R. Rifabutin-Based Rescue Therapy for *Helicobacter pylori* Eradication: A Long-Term Prospective Study in a Large Cohort of Difficult-to-Treat Patients. *J Clin Med*. 2019 Feb 6;8(2):199. doi: 10.3390/jcm8020199. PMID: 30736338; PMCID: PMC6406425.
47. Vernero M, Astegiano M, Ribaldone DG. New Onset of Inflammatory Bowel Disease in Three Patients Undergoing IL-17A Inhibitor Secukinumab: A Case Series. *Am J Gastroenterol*. 2019 Jan;114(1):179-180. Doi: 10.1038/s41395-018-0422-z. PMID: 30429591.
48. Italian Association for the Study of the Liver (AISF). AISF position paper on HCV in immunocompromised patients. *Dig Liver Dis*. 2019 Jan;51(1):10-23. Doi: 10.1016/j.dld.2018.09.022. Epub 2018 Oct 1. PMID: 30366813.
49. Faletti R, Ribaldone DG, Gatti M, Perazzini C, Robella M, Angelino F, Saracco GM, Astegiano M, Pellicano R, Fonio P. Apparent diffusion coefficient and enhancement patterns in MR imaging as markers of severe or moderate ileum inflammation in Crohn's disease. *Rev Esp Enferm Dig*. 2019 Jan;111(1):28-33. Doi: 10.17235/reed.2018.5691/2018. PMID: 30284909.
50. Ribaldone DG, Astegiano M. Comment #2 on "First-Line *Helicobacter pylori* Eradication with Vonoprazan, Clarithromycin, and Metronidazole in Patients Allergic to Penicillin". *Gastroenterol Res Pract*. 2018 Dec 16;2018:5260358. doi: 10.1155/2018/5260358. PMID: 30647734; PMCID: PMC6311862.
51. Adriani A, Ribaldone DG, Astegiano M, Durazzo M, Saracco GM, Pellicano R. Irritable bowel syndrome: the clinical approach. *Panminerva Med*. 2018 Dec;60(4):213-222. doi: 10.23736/S0031-0808.18.03541-3. Epub 2018 Sep 24. PMID: 30257542.
52. Ribaldone DG, Vernero M, Astegiano M, Pellicano R. How ameliorate the adherence in patients with inflammatory bowel disease? *Scand J Gastroenterol*. 2018 Aug;53(8):938-939. doi: 10.1080/00365521.2018.1485731. Epub 2018 Jul 3. PMID: 29969048.
53. Ribaldone DG, Dileo I, Pellicano R, Resegotti A, Fagoonee S, Vernero M, Saracco G, Astegiano M. Severe ulcerative colitis: predictors of response and algorithm proposal for rescue therapy. *Ir J Med Sci*. 2018 May;187(2):385-392. doi: 10.1007/s11845-017-1666-0. Epub 2017 Jul 29. PMID: 28756540.
54. Ribaldone DG, Mazzucco D, Fagoonee S, Crocellà L, Lavagna A, Fracchia M, Caviglia GP, Simondi D, Rocca R, Astegiano M. Management of *Helicobacter pylori* in Piedmont, Italy. *Minerva Gastroenterol Dietol*. 2018 Feb 19. doi: 10.23736/S1121-421X.18.02483-2. [Epub ahead of print] PubMed PMID: 29458241.
55. Ribaldone DG, Astegiano M, Pellicano R. *Helicobacter pylori* eradication: poor medical compliance from East to West of the world. *Scand J Gastroenterol*. 2018 Mar;53(3):265. doi: 10.1080/00365521.2018.1433231. Epub 2018 Jan 31. PubMed PMID:29383955.
56. Caviglia GP, Ribaldone DG, Rosso C, Saracco GM, Astegiano M, Pellicano R. Fecal calprotectin: beyond intestinal organic diseases. *Panminerva Med*. 2018 Mar;60(1):29-34. doi: 10.23736/S0031-0808.18.03405-5. Epub 2018 Jan 25. PubMed PMID: 29370679.
57. Pellicano R, Ribaldone DG, Astegiano M, Dughera L, Battaglia E, Morgando A, Arrigoni A, Spandre M, Grassini M, Saracco GM, Mégraud F. Gastroenterology today: between certainties and news: a meeting held in Turin on May 27, 2017. *Minerva Gastroenterol Dietol*. 2018 Jan 10. doi: 10.23736/S1121-421X.18.02465-0. [Epub ahead of print] PubMed PMID: 29327820.
58. Ribaldone DG, Saracco GM, Astegiano M, Pellicano R. Letter: therapeutic drug monitoring and inflammatory bowel disease—a call for an urgent standardization of the results. *Aliment Pharmacol Ther*. 2018 Feb;47(3):448-449. doi: 10.1111/apt.14456. PubMed PMID: 29314133.

59. Ribaldone DG, Venero M, Saracco GM, Pellicano R, Finocchiaro F, Caviglia GP, Astegiano M. The adherence to the therapy in inflammatory bowel disease: beyond the number of the tablets. *Scand J Gastroenterol.* 2018 Feb;53(2):141-146. doi: 10.1080/00365521.2017.1405070. Epub 2017 Dec 11. PubMed PMID: 29228844.
60. Ribaldone DG, Saracco G, Astegiano M, Pellicano R. Letter: biologics treatment in Crohn's disease and risk of bowel resection-what about the patients who stop anti-TNF therapy? *Aliment Pharmacol Ther.* 2018 Jan;47(1):146-147. doi: 10.1111/apt.14321. PubMed PMID: 29226397.
61. Ribaldone DG, Saracco GM, Astegiano M, Pellicano R. Efficacy of infliximab biosimilars in patients with Crohn's disease. *Lancet.* 2017 Dec 2;390(10111):2435-2436. doi: 10.1016/S0140-6736(17)33047-7. Epub 2017 Dec 1. PubMed PMID: 29208303.
62. Ribaldone DG, Manetta T, Mengozzi G, Saracco GM, Pellicano R, Astegiano M. Adalimumab trough levels predict Crohn's disease clinical course. *Dig Liver Dis.* 2018 Feb;50(2):204-206. doi: 10.1016/j.dld.2017.09.139. Epub 2017 Oct 28. PubMed PMID: 29129478.
63. Ribaldone DG, Astegiano M. Biosimilar CT-P13 in treating ulcerative colitis in the real world. *Minerva Gastroenterol Dietol.* 2017 Dec;63(4):305-306. doi: 10.23736/S1121-421X.17.02423-0. PubMed PMID: 28927246.
64. Ribaldone DG, Dileo I, Pellicano R, Resegotti A, Fagoonee S, Venero M, Saracco G, Astegiano M. Severe ulcerative colitis: predictors of response and algorithm proposal for rescue therapy. *Ir J Med Sci.* 2017 Jul 29. doi: 10.1007/s11845-017-1666-0. [Epub ahead of print] PubMed PMID: 28756540.
65. Ribaldone DG, Simondi D, Manca A, Demarchi B, Pulitanò R, Astegiano M, Pellicano R. Features of inflammatory bowel disease followed in a second level center in Northern Italy. *Minerva Med.* 2017 Oct;108(5):481-482. doi: 10.23736/S0026-4806.17.05118-7. PubMed PMID: 28728343.
66. Caviglia GP, Sguazzini C, Cisarò F, Ribaldone DG, Rosso C, Fagoonee S, Smedile A, Saracco GM, Astegiano M, Pellicano R. Gastric emptying and related symptoms in patients treated with buspirone, amitriptyline or clobopride: a "real world" study by <sup>13</sup>C-octanoic Acid Breath Test. *Minerva Med.* 2017 Dec;108(6):489-495. doi: 10.23736/S0026-4806.17.05320-4. Epub 2017 Jul 12. PubMed PMID: 28707862.
67. Ribaldone DG, Astegiano M, Saracco G, Pellicano R. Amoxicillin and Metronidazole Therapy for Helicobacter pylori Eradication: A 10-Year Trend in Turin, Italy. *Balkan Med J.* 2017 May 5;34(3):290-291. doi: 10.4274/balkanmedj.2015.1714. PubMed PMID: 28559221; PubMed Central PMCID: PMC5450874.
68. Ribaldone DG, Astegiano M, Pellicano R. The role of hepatic enzymes in Crohn's disease. *Int J Colorectal Dis.* 2017 Sep;32(9):1363-1364. doi: 10.1007/s00384-017-2829-1. Epub 2017 May 4. PubMed PMID: 28474260.
69. Vanoli A, Di Sabatino A, Furlan D, Klersy C, Grillo F, Fiocca R, Mescoli C, Ruge M, Nesi G, Fociani P, Sampietro G, Ardizzone S, Luinetti O, Calabrò A, Tonelli F, Volta U, Santini D, Caio G, Giuffrida P, Elli L, Ferrero S, Latella G, Ciardi A, Caronna R, Solina G, Rizzo A, Ciacci C, D'Armiento FP, Salemme M, Villanacci V, Cannizzaro R, Canzonieri V, Reggiani Bonetti L, Biancone L, Monteleone G, Orlandi A, Santeusano G, Macciomei MC, D'Inca R, Perfetti V, Sandri G, Silano M, Florena AM, Giannone AG, Papi C, Coppola L, Usai P, Maccioni A, Astegiano M, Migliora P, Manca R, Martino M, Trapani D, Cerutti R, Alberizzi P, Riboni R, Sessa F, Paulli M, Solcia E, Corazza GR. Small Bowel Carcinomas in Coeliac or Crohn's Disease: Clinico-pathological, Molecular, and Prognostic Features. A Study From the Small Bowel Cancer Italian Consortium. *J Crohns Colitis.* 2017 Aug 1;11(8):942-953. doi: 10.1093/ecco-jcc/jjx031. PubMed PMID: 28333239.
70. Savarino V, Pace F, Scarpignato C; Esoxx Study Group. Randomised clinical trial: mucosal protection combined with acid suppression in the treatment of non-erosive reflux disease - efficacy of Esoxx, a hyaluronic acid-chondroitin sulphate based bioadhesive formulation. *Aliment Pharmacol Ther.* 2017 Mar;45(5):631-642. doi: 10.1111/apt.13914. Epub 2017 Jan 24. PubMed PMID: 28116754; PubMed Central PMCID: PMC5347926.
71. Pellicano R, Ribaldone DG, Fagoonee S, Astegiano M, Saracco GM. The first-line treatment of Helicobacter pylori infection in Piedmont in the year 2017. *Panminerva Med.* 2017 Jun;59(2):199. doi: 10.23736/S0031-0808.17.03291-8. Epub 2017 Jan 17. PubMed PMID: 28094491.
72. Bonagura GA, Ribaldone DG, Fagoonee S, Sapone N, Caviglia GP, Saracco GM, Astegiano M, Pellicano R. Microscopic colitis in patients with mild duodenal damage: A new clinical and pathological entity ("lymphocytic enterocolitis")? *World J Gastrointest Pathophysiol.* 2016 Nov 15;7(4):307-313. PubMed PMID: 27895976; PubMed Central PMCID: PMC5108976.
73. Pellicano R, Ribaldone DG, Fagoonee S, Astegiano M, Saracco GM, Mégraud F. A 2016 panorama of Helicobacter pylori infection: key messages for clinicians. *Panminerva Med.* 2016 Dec;58(4):304-317. Review. PubMed PMID: 27716738.

74. Resegotti A, Silvestri S, Astegiano M, Deiro G, Ribaldone D, Cassine D, Franchello A. "Small is beautiful" A series of ileo-anal anastomoses performed with the 25 - mm circular stapler. *Ann Ital Chir.* 2016;87:186-91. PubMed PMID: 27179235.
75. Younes R, Astegiano M. Is vitamin B12 serum level involved in the spread of *Helicobacter pylori*? *Minerva Gastroenterol Dietol.* 2016 Jun;62(2):225. PubMed PMID: 27091039.
76. Ribaldone DG, Conti L, Resegotti A, Astegiano M. Adnexal localization of Crohn's disease and recurrent massive ovary cysts. *Rev Esp Enferm Dig.* 2016 Aug;108(8):525-6. doi: 10.17235/reed.2016.4301/2016. PubMed PMID: 27032386.
77. Ribaldone DG, Simondi D, Astegiano M, Pellicano R. On Inverse Association Between *Helicobacter pylori* Gastritis and Microscopic Colitis: The European Data. *Inflamm Bowel Dis.* 2016 Mar;22(3):E11-2. doi: 10.1097/MIB.0000000000000704. PubMed PMID: 26871398.
78. Ribaldone DG, Fagoonee S, Astegiano M, De Angelis C, Smedile A, Caviglia GP, Petrini E, Greco A, Pellicano R. Coxib's Safety in Patients with Inflammatory Bowel Diseases: A Meta-analysis. *Pain Physician.* 2015 Nov;18(6):599-607. Review. Erratum in: *Pain Physician.* 2016 Feb;19(2):101. PubMed PMID: 26606012.
79. Ribaldone DG, Garavagno M, Pellicano R, Bresso F, Fagoonee S, David E, Sapone N, Bonagura AG, Resegotti A, Astegiano M. Prevalence and prognostic value of hepatic histological alterations in patients with Crohn's disease. *Scand J Gastroenterol.* 2015;50(12):1463-8. doi: 10.3109/00365521.2015.1064995. Epub 2015 Jul 2. PubMed PMID: 26133749.
80. Reggiani S, Cosso L, Adriani A, Pantaleoni S, Risso A, Vittone F, Chiusa L, Sapone N, Astegiano M. A Case of Intestinal Mastocytosis Misdiagnosed as Crohn's Disease. *Case Rep Gastroenterol.* 2015 Jun 3;9(2):188-93. doi: 10.1159/000430946. eCollection 2015 May-Aug. PubMed PMID: 26120300; PubMed Central PMCID: PMC4478337.
81. Greco A, Caviglia GP, Brignolo P, Ribaldone DG, Reggiani S, Sguazzini C, Smedile A, Pellicano R, Resegotti A, Astegiano M, Bresso F. Glucose breath test and Crohn's disease: Diagnosis of small intestinal bacterial overgrowth and evaluation of therapeutic response. *Scand J Gastroenterol.* 2015;50(11):1376-81. doi: 10.3109/00365521.2015.1050691. Epub 2015 May 19. PubMed PMID: 25990116.
82. Ribaldone DG, Fagoonee S, Astegiano M, Saracco G, Pellicano R. Efficacy of amoxicillin and clarithromycin-based triple therapy for *Helicobacter pylori* eradication: a 10-year trend in Turin, Italy. *Panminerva Med.* 2015 Sep;57(3):145-6. PubMed PMID: 25971330.
83. Simondi D, Ribaldone DG, Bonagura GA, Foi S, Sapone N, Garavagno M, Villanacci V, Bernardi D, Pellicano R, Rizzetto M, Astegiano M. *Helicobacter pylori* in celiac disease and in duodenal intraepithelial lymphocytosis: Active protagonist or innocent bystander? *Clin Res Hepatol Gastroenterol.* 2015 Dec;39(6):740-5. doi: 10.1016/j.clinre.2015.03.005. Epub 2015 May 5. PubMed PMID: 25956489.
84. Silvestri S, Falcone A, Franchello A, Guglielmino V, Cassine D, Astegiano M, Resegotti A. The mesenteric flap: a technique for pelvic closure after proctectomy for Crohn's disease. *Colorectal Dis.* 2015 Jun;17(6):543-4. doi: 10.1111/codi.12973. PubMed PMID: 25880258.
85. Ribaldone DG, Cammarota T, Resegotti A, Sarno A, Robotti D, Deboni P, Bonenti G, Bresso F, Pellicano R, Adriani A, Sguazzini C, Reggiani S, Astegiano M. Power Doppler sonography to predict the risk of surgical recurrence of Crohn's disease. *J Ultrasound.* 2014 Jun 12;18(1):51-5. doi: 10.1007/s40477-014-0101-x. eCollection 2015 Mar. PubMed PMID: 25767640; PubMed Central PMCID: PMC4353824.
86. Caviglia GP, Pellicano R, Astegiano M. Reply to: Diagnostic power of fecal calprotectin in inflammatory and functional intestinal disorders. *Scand J Gastroenterol.* 2015 May;50(5):623-4. doi: 10.3109/00365521.2014.1002527. Epub 2015 Mar 3. PubMed PMID: 25737251.
87. Ribaldone DG, Cammarota T, Resegotti A, Astegiano M. A preserved stratified pattern of the bowel wall 1 year after major surgery does not influence the surgical recurrence of Crohn's disease. *Ir J Med Sci.* 2016 Feb;185(1):269-70. doi: 10.1007/s11845-015-1249-x. Epub 2015 Jan 13. PubMed PMID: 25579769.
88. Tursi A, Brandimarte G, Di Mario F, Andreoli A, Annunziata ML, Astegiano M, Bianco MA, Buri L, Cammarota G, Capezzuto E, Chilovi F, Cianci M, Conigliaro R, Del Favero G, Di Cesare L, Di Fonzo M, Elisei W, Faggiani R, Farroni F, Forti G, Germanà B, Giorgetti GM, Giovannone M, Lecca PG, Loperfido S, Marmo R, Morucci P, Occhigrossi G, Penna A, Rossi AF, Spadaccini A, Zampaletta C, Zilli M, Zullo A, Scarpignato C, Picchio M. Development and validation of an endoscopic classification of diverticular disease of the colon: the DICA classification. *Dig Dis.* 2015;33(1):68-76. doi: 10.1159/000366039. Epub 2014 Dec 17. PubMed PMID: 25531499.

89. Pellicano R, Ribaldone DG, Saracco GM, Leone N, De Angelis C, Arrigoni A, Morello E, Sapone N, Cisarò F, Astegiano M. Benefit of supplements in functional dyspepsia after treatment of *Helicobacter pylori*. *Minerva Gastroenterol Dietol*. 2014 Dec;60(4):263-8. PubMed PMID: 25384804.
90. Pantaleoni S, Luchino M, Adriani A, Pellicano R, Stradella D, Ribaldone DG, Sapone N, Isaia GC, Di Stefano M, Astegiano M. Bone mineral density at diagnosis of celiac disease and after 1 year of gluten-free diet. *ScientificWorldJournal*. 2014;2014:173082. doi: 10.1155/2014/173082. Epub 2014 Oct 14. PubMed PMID: 25379519; PubMed Central PMCID: PMC4213989.
91. Caviglia GP, Pantaleoni S, Touscoz GA, Adriani A, Rosso C, Smedile A, Pellicano R, Astegiano M, Bresso F. Fecal calprotectin is an effective diagnostic tool that differentiates inflammatory from functional intestinal disorders. *Scand J Gastroenterol*. 2014 Dec;49(12):1419-24. doi: 10.3109/00365521.2014.934913. Epub 2014 Nov 5. PubMed PMID: 25369978.
92. Biagi F, Marchese A, Ferretti F, Ciccocioppo R, Schieppatti A, Volta U, Caio G, Ciacci C, Zingone F, D'Odorico A, Carroccio A, Ambrosiano G, Mansueto P, Gasbarrini A, Piscaglia AC, Andrealli A, Astegiano M, Segato S, Neri M, Meggio A, de Pretis G, De Vitis I, Gobbi P, Corazza GR. A multicentre case control study on complicated coeliac disease: two different patterns of natural history, two different prognoses. *BMC Gastroenterol*. 2014 Aug 7;14:139. doi: 10.1186/1471-230X-14-139. PubMed PMID: 25103857; PubMed Central PMCID: PMC4127435.
93. Adriani A, Pantaleoni S, Luchino M, Ribaldone DG, Reggiani S, Sapone N, Sguazzini C, Isaia G, Pellicano R, Astegiano M. Osteopenia and osteoporosis in patients with new diagnosis of inflammatory bowel disease. *Panminerva Med*. 2014 Jun;56(2):145-9. PubMed PMID: 24994578.
94. De Nicolò A, Agnesod D, Simiele M, Riganò D, Adriani A, Canaparo R, Astegiano M, Rizzetto M, Di Perri G, D'Avolio A. UPLC-MS/MS method for quantification of the azathioprine metabolites 6-mercaptopguanosine and 6-methylmercaptopurine riboside in peripheral blood mononuclear cells. *J Pharm Biomed Anal*. 2014 Sep;98:271-8. doi: 10.1016/j.jpba.2014.05.040. Epub 2014 Jun 7. PubMed PMID: 24960235.
95. Biagi F, Schieppatti A, Malamut G, Marchese A, Cellier C, Bakker SF, Mulder CJ, Volta U, Zingone F, Ciacci C, D'Odorico A, Andrealli A, Astegiano M, Klersy C, Corazza GR. PROgnosticating COeliac patieNts SURvival: the PROCONSUL score. *PLoS One*. 2014 Jan 2;9(1):e84163. doi: 10.1371/journal.pone.0084163. eCollection 2014. PubMed PMID: 24392112; PubMed Central PMCID: PMC3879269.
96. Fagoonee S, Astegiano M, Smedile A, Pellicano R. Efficacy of cefixime-based triple therapy for *Helicobacter pylori* eradication: a retrospective study. *Panminerva Med*. 2013 Sep;55(3):309-10. PubMed PMID: 24088806.
97. Adriani A, Astegiano M, Smedile A, Rizzetto M, Pellicano R. Efficacy of cefixime plus metronidazole therapy for *Helicobacter pylori* eradication: a retrospective study. *Minerva Med*. 2013 Aug;104(4):495-6. PubMed PMID: 24008612.
98. Pellicano R, De Angelis C, Ribaldone DG, Fagoonee S, Astegiano M. 2013 update on celiac disease and eosinophilic esophagitis. *Nutrients*. 2013 Aug 22;5(9):3329-36. doi: 10.3390/nu5093329. Review. PubMed PMID: 23974065; PubMed Central PMCID: PMC3798906.
99. Cammarota T, Ribaldone DG, Resegotti A, Repici A, Danese S, Fiorino G, Sarno A, Robotti D, Deboni P, Bonenti G, Pellicano R, Andrealli A, Sapone N, Simondi D, Bresso F, Astegiano M. Role of bowel ultrasound as a predictor of surgical recurrence of Crohn's disease. *Scand J Gastroenterol*. 2013 May;48(5):552-5. doi: 10.3109/00365521.2013.777774. Epub 2013 Mar 11. PubMed PMID: 23477675.
100. Canavese G, Bassotti G, Astegiano M, Castellano I, Cassoni P, Sapino A, Villanacci V. Inflammatory bowel disease: a proposal to facilitate the achievement of an unequivocal diagnosis. *World J Gastroenterol*. 2013 Jan 21;19(3):426-8. doi: 10.3748/wjg.v19.i3.426. PubMed PMID: 23372370; PubMed Central PMCID: PMC3554832.
101. Pallavicino F, Pellicano R, Reggiani S, Simondi D, Sguazzini C, Bonagura AG, Cisarò F, Rizzetto M, Astegiano M. Inflammatory bowel diseases and primary sclerosing cholangitis: hepatic and pancreatic side effects due to azathioprine. *Eur Rev Med Pharmacol Sci*. 2013 Jan;17(1):84-7. PubMed PMID: 23329527.
102. Marchese A, Klersy C, Biagi F, Balduzzi D, Bianchi PI, Trotta L, Vattiato C, Zilli A, Rademacher J, Andrealli A, Astegiano M, Michelini I, Häuser W, Corazza GR. Quality of life in coeliac patients: Italian validation of a coeliac questionnaire. *Eur J Intern Med*. 2013 Jan;24(1):87-91. doi: 10.1016/j.ejim.2012.09.015. Epub 2012 Oct 25. PubMed PMID: 23102568.

103. Ferraro PM, D'Ovidio V, Bresci G, Astegiano M, Principi B, D'Inca' R, Testa R, Valpiani D, Guidi L, Armuzzi A, Costa F, Aratari A, Vecchi M, De Franchis R, Di Leo V, Ricci C, Riegler G, Colombo E, Repaci G, Lecis P, Silla M, Passalacqua S. [Predictors of clinical response in patients with ulcerative colitis treated with granulocyte-monocyte apheresis: analysis of the apheresis registry data]. *G Ital Nefrol.* 2012 Jan-Feb;29 Suppl 54:S144-6. Italian. PubMed PMID: 22388848.
104. Biagi F, Bianchi PI, Marchese A, Trotta L, Vattiato C, Balduzzi D, Brusco G, Andrealli A, Cisarò F, Astegiano M, Pellegrino S, Magazzù G, Klersy C, Corazza GR. A score that verifies adherence to a gluten-free diet: a cross-sectional, multicentre validation in real clinical life. *Br J Nutr.* 2012 Nov 28;108(10):1884-8. doi: 10.1017/S0007114511007367. Epub 2012 Feb 10. PubMed PMID: 22321199.
105. Ribaldone DG, Astegiano M, Fagoonee S, Rizzetto M, Pellicano R. Epilepsy and celiac disease: review of literature. *Panminerva Med.* 2011 Dec;53(4):213-6. Review. PubMed PMID: 22146418.
106. Passalacqua S, Ferraro PM, Bresci G, D'Ovidio V, Astegiano M, Principi M, Testa R, D'Inca' R, Valpiani D, Armuzzi A, Sablich R, Cavallaro F, Costa F, Di Leo V, Colombo E, Santini A, Aratari A, Lecis P, Saladino V, Riegler G, Marco M, Calella F, Ricci C, Guidi ML, Repaci G, Silla M. The Italian Registry of Therapeutic Apheresis: granulocyte-monocyte apheresis in the treatment of inflammatory bowel disease. A multicentric study. *J Clin Apher.* 2011 Dec;26(6):332-7. doi: 10.1002/jca.20315. Epub 2011 Nov 9. PubMed PMID: 22072543.
107. Pellicano R, Sostegni R, Sguazzini C, Reggiani S, Astegiano M. A rare location of Crohn's disease: the nasal mucosa. *Acta Biomed.* 2011 Apr;82(1):74-6. PubMed PMID: 22069960.
108. Biasi F, Astegiano M, Maina M, Leonarduzzi G, Poli G. Polyphenol supplementation as a complementary medicinal approach to treating inflammatory bowel disease. *Curr Med Chem.* 2011;18(31):4851-65. Review. PubMed PMID: 21919842.
109. Cisarò F, Astegiano M, De Angelis C, Saracco G, Rizzetto M, Pellicano R. Ranitidine bismuth citrate in the first-line of *Helicobacter pylori* treatment. *Panminerva Med.* 2011 Jun;53(2):138. PubMed PMID: 21659979.
110. Pellicano R, Fagoonee S, Astegiano M, Morgando A, Cisarò F, Rizzetto M. Amoxicillin plus tetracycline as first-line *Helicobacter pylori* treatment. *Minerva Med.* 2011 Apr;102(2):169-70. PubMed PMID: 21483404.
111. Berrutti M, Fagoonee S, Strona S, Astegiano M, Morgando A, Rizzetto M, Pellicano R. *Minerva Med.* 2010 Dec;101(6):457-8. No abstract available. Efficacy of clarithromycin plus metronidazole-based triple therapy for *Helicobacter pylori* eradication: a retrospective study.
112. Efficacy of amoxicillin plus clavulanic acid-based triple therapy for *Helicobacter pylori* eradication: a retrospective study. Berrutti M, Astegiano M, Smedile A, Fagoonee S, Rizzetto M, Pellicano R. *Panminerva Med.* 2010 Dec;52(4):361-2. No abstract available.
113. Prevalence of *Helicobacter pylori* infection in patients with inflammatory bowel disease: pilot study. Pellicano R, Bresso F, Demarchi B, Bertolusso L, Sapone N, Rizzetto M, Astegiano M. *Rev Esp Enferm Dig.* 2010 Nov;102(11):675-6; author reply 676. No abstract available.
114. A retrospective study on a cohort of patients with lymphocytic colitis. Simondi D, Pellicano R, Reggiani S, Pallavicino F, David E, Sguazzini C, Bonagura AG, La Terra A, Rizzetto M, Astegiano M. *Rev Esp Enferm Dig.* 2010 Jun;102(6):381-4.
115. A 2010 panorama on diseases of the small and large intestine. Pellicano R, Astegiano M, Rizzetto M. *Minerva Gastroenterol Dietol.* 2010 Mar;56(1):25-6.
116. Anal transitional zone adenocarcinoma following restorative proctocolectomy for ulcerative colitis: case report and review of literature. Panier-Suffat L, Marracino M, Resegotti A, Astegiano M, Giustetto A, Garino M, Pellicano R, Fronda G. *Acta Gastroenterol Belg.* 2009 Oct-Dec;72(4):441-3.
117. Clinical and biochemical parameters related to cardiovascular disease after *Helicobacter pylori* eradication. Pellicano R, Oliaro E, Fagoonee S, Astegiano M, Berrutti M, Saracco G, Smedile A, Repaci A, Leone N, Castelli A, Luigiano C, Fadda M, Rizzetto M. *Int Angiol.* 2009 Dec;28(6):469-73.
118. Benefit of dietary integrators for treating functional dyspepsia: a prospective pilot study. Pellicano R, Strona S, Simondi D, Reggiani S, Pallavicino F, Sguazzini C, Bonagura AG, Rizzetto M, Astegiano M. *Minerva Gastroenterol Dietol.* 2009 Sep;55(3):227-35. English, Italian.
119. Pro-oxidant and proapoptotic effects of cholesterol oxidation products on human colonic epithelial cells: a potential mechanism of inflammatory bowel disease progression. Biasi F, Mascia C, Astegiano M, Chiarpotto E, Nano M, Vizio B, Leonarduzzi G, Poli G. *Free Radic Biol Med.* 2009 Dec 15;47(12):1731-41. Epub 2009 Sep 22.

120. High rate of microscopic colitis in patients with Marsh I-II duodenal damage. Astegiano M, Pellicano R, Verme G, Rizzetto M. *Scand J Gastroenterol.* 2009;44(10):1266-7. No abstract available.
121. Internet use among inflammatory bowel disease patients: an Italian multicenter survey. Angelucci E, Orlando A, Ardizzone S, Guidi L, Sorrentino D, Fries W, Astegiano M, Sociale O, Cesarini M, Renna S, Cassinotti A, Marzo M, Quaglia A, Sergi MD, Simondi D, Vernia P, Malesci A, Danese S. *Eur J Gastroenterol Hepatol.* 2009 Sep;21(9):1036-41.
122. Methodology and indications of H2-breath testing in gastrointestinal diseases: the Rome Consensus Conference. Gasbarrini A, Corazza GR, Gasbarrini G, Montalto M, Di Stefano M, Basilisco G, Parodi A, Usai-Satta P, Vernia P, Anania C, Astegiano M, Barbara G, Benini L, Bonazzi P, Capurso G, Certo M, Colecchia A, Cuoco L, Di Sario A, Festi D, Lauritano C, Miceli E, Nardone G, Perri F, Portincasa P, Riscato R, Sorge M, Tursi A; 1st Rome H2-Breath Testing Consensus Conference Working Group. *Aliment Pharmacol Ther.* 2009 Mar 30;29 Suppl 1:1-49. Erratum in: *Aliment Pharmacol Ther.* 2010 Jan;31(1):166. Satta PU [corrected to Usai-Satta P].
123. Risk factors for HCV infection. Focus on ethnic and cultural characteristics. Pellicano R, De Angelis C, De Luca L, Smedile A, Berrutti M, Astegiano M, Rizzetto M. *Minerva Gastroenterol Dietol.* 2009 Jun;55(2):159-62. Review..
124. US evaluation of patients affected by IBD: how to do it, methods and findings. Cammarota T, Sarno A, Robotti D, Bonenti G, Debani P, Versace K, Astegiano M, Pera A. *Eur J Radiol.* 2009 Mar;69(3):429-37. Epub 2009 Jan 3. Review.
125. Helicobacter pylori eradication: metronidazole or tinidazole? Data from Turin, Italy. Berrutti M, Pellicano R, Astegiano M, Smedile A, Saracco G, Morgando A, De Angelis C, Repici A, Fagoonee S, Leone N, Rizzetto M. *Minerva Gastroenterol Dietol.* 2008 Dec;54(4):355-8.
126. Efficacy of azythromycin-based triple therapy for Helicobacter pylori infection: a retrospective study. Pellicano R, Astegiano M, Smedile A, Saracco G, Berrutti M, Morgando A, Fadda M, Repici A, Fagoonee S, Rizzetto M. *Panminerva Med.* 2008 Sep;50(3):259-60. No abstract available.
127. Helicobacter pylori and type 2 diabetes mellitus. Negative results and goals of future studies. Pellicano R, Astegiano M, Rizzetto M. *Saudi Med J.* 2008 Aug;29(8):1213. No abstract available.
128. Identification of a new WASP and FKBP-like (WAFL) protein in inflammatory bowel disease: a potential marker gene for ulcerative colitis. Viklund IM, Kuznetsov NV, Löfberg R, Daperno M, Sostegni R, Astegiano M, Rizzetto M, von Stein O, D'Amato M, von Stein P, Pettersson S. *Int J Colorectal Dis.* 2008 Oct;23(10):921-30. Epub 2008 Jul 25.
129. 2008 Clinical approach to irritable bowel syndrome. Astegiano M, Pellicano R, Sguazzini C, Berrutti M, Simondi D, Reggiani S, Rizzetto M. *Minerva Gastroenterol Dietol.* 2008 Sep;54(3):251-7. Review.
130. Potential relationship between Helicobacter pylori and ischemic heart disease: any pathogenic model? Berrutti M, Pellicano R, Fagoonee S, Astegiano M, Smedile A, Saracco G, Repici A, Leone N, Rizzetto M. *Panminerva Med.* 2008 Jun;50(2):161-3. Review.
131. Differential regulation of interleukin 12 and interleukin 23 production in human dendritic cells. Gerosa F, Baldani-Guerra B, Lyakh LA, Batoni G, Esin S, Winkler-Pickett RT, Consolaro MR, De Marchi M, Giachino D, Robbiano A, Astegiano M, Sambataro A, Kastelein RA, Carra G, Trinchieri G. *J Exp Med.* 2008 Jun 9;205(6):1447-61. Epub 2008 May 19.
132. A 2008 panorama on osteoporosis and inflammatory bowel disease. Sapone N, Pellicano R, Simondi D, Sguazzini C, Reggiani S, Terzi E, Rizzetto M, Astegiano M. *Minerva Med.* 2008 Feb;99(1):65-71. Review.
133. [Antiglican antibodies as serological markers in the differential diagnosis of inflammatory bowel disease.](#) Simondi D, Mengozzi G, Betteto S, Bonardi R, Ghignone RP, Fagoonee S, Pellicano R, Sguazzini C, Pagni R, Rizzetto M, Astegiano M. *Inflamm Bowel Dis.* 2008 May;14(5):645-51.
134. Hepatocellular carcinoma complicating primary sclerosing cholangitis in Crohn's disease. A case report. Demarchi B, Bresso F, Novero D, Palestro G, Sapone N, Pellicano R, Bonardi R, Smedile A, Rizzetto M, Astegiano M. *Minerva Gastroenterol Dietol.* 2007 Sep;53(3):279-83.
135. Neuropeptide s receptor 1 gene polymorphism is associated with susceptibility to inflammatory bowel disease. D'Amato M, Bruce S, Bresso F, Zucchelli M, Ezer S, Pulkkinen V, Lindgren C, Astegiano M, Rizzetto M, Gionchetti P, Riegler G, Sostegni R, Daperno M, D'Alfonso S, Momigliano-Richiardi P, Torkvist L, Puolakkainen P, Lappalainen M, Paavola-Sakki P, Halme L, Farkkila M, Turunen U, Kontula K, Lofberg R, Pettersson S, Kere J. *Gastroenterology.* 2007 Sep;133(3):808-17. Epub 2007 Jun 20.
136. Women and celiac disease: association with unexplained infertility. Pellicano R, Astegiano M, Bruno M, Fagoonee S, Rizzetto M. *Minerva Med.* 2007 Jun;98(3):217-9. Review.

137. [Helicobacter pylori and gastro-esophageal reflux disease: clinical considerations]. Berrutti M, Fagoonee S, Astegiano M, Pellicano R, Rizzetto M. *Minerva Gastroenterol Dietol.* 2007 Jun;53(2):153-6. Review. Italian.
138. Assessment of liver fibrosis in the clinical setting: something is changing? Berrutti M, Ciancio A, Smedile A, Brunello F, Bonardi R, Pellicano R, Astegiano M, Sapone N, Touscoz GA, Rizzetto M. *Minerva Gastroenterol Dietol.* 2007 Mar;53(1):111-4. Review.
139. Efficacy and safety of oral beclomethasone dipropionate for ileal or ileal-right colon Crohn's disease of mild-to-moderate activity or in remission: Retrospective study. Astegiano M, Pagano N, Sapone N, Simondi D, Bertolusso L, Bresso F, Demarchi B, Pellicano R, Bonardi R, Marconi S, Rizzetto M. *Biomed Pharmacother.* 2007 Jul;61(6):370-6. Epub 2007 Mar 12.
140. [Helicobacter pylori and headache: a minireview]. Pellicano R, Savi L, De Martino P, Morgando A, Astegiano M, Pinessi L, Rizzetto M. *Minerva Med.* 2007 Feb;98(1):37-41. Review. Italian.
141. [Gastroenterology outpatient clinic of the Molinette Hospital (Turin, Italy): the 2003-2006 report]. Pellicano R, Bonardi R, Smedile A, Saracco G, Ponzetto A, Lagget M, Morgando A, Balzola F, Bruno M, Marzano A, Ponti V, Debernardi Venon W, Ciancio A, Rizzetto M, Astegiano M. *Minerva Med.* 2007 Feb;98(1):19-23. Italian.
142. Updated review (2006) on Helicobacter pylori as a potential target for the therapy of ischemic heart disease. Pellicano R, Peyre S, Astegiano M, Oliaro E, Fagoonee S, Rizzetto M. *Panminerva Med.* 2006 Dec;48(4):241-6. Review.
143. Potential role for the common cystic fibrosis DeltaF508 mutation in Crohn's disease. Bresso F, Askling J, Astegiano M, Demarchi B, Sapone N, Rizzetto M, Gionchetti P, Lammers KM, de Leone A, Riegler G, Nimmo ER, Drummond H, Noble C, Torkvist L, Ekbohm A, Zucchelli M, Lofberg R, Satsangi J, Pettersson S, D'Amato M. *Inflamm Bowel Dis.* 2007 May;13(5):531-6.
144. Treatment of irritable bowel syndrome. A case control experience. Astegiano M, Pellicano R, Terzi E, Simondi D, Rizzetto M. *Minerva Gastroenterol Dietol.* 2006 Dec;52(4):359-63.
145. [Invasive diagnosis of Helicobacter pylori infection in the 2006 clinical practice]. Repici A, Pellicano R, Astegiano M, Saracco G, De Angelis C, Debernardi W, Berrutti M, Rizzetto M. *Minerva Med.* 2006 Feb;97(1):25-9. Review. Italian.
146. [Non-invasive diagnosis of Helicobacter pylori infection in the 2006 clinical practice]. Pellicano R, Astegiano M, Smedile A, Bonardi R, Morgando A, Repici A, Rizzetto M. *Minerva Med.* 2006 Feb;97(1):19-24. Review. Italian.
147. Helicobacter pylori and ischemic heart disease. Which potential pathogenic mechanisms? Pellicano R, Astegiano M, Rizzetto M. *Saudi Med J.* 2006 Mar;27(3):427; author reply 428. No abstract available.
148. Diagnosis of Helicobacter pylori infection: validation of a commercial non invasive salivary test against urea breath test and serology. Pellicano R, Vanni E, Palmas F, Astegiano M, Leone N, Fagoonee S, Ponzetto A, Rizzetto M. *Minerva Gastroenterol Dietol.* 2001 Sep;47(3):111-6.
149. [Abdominal pain and bowel dysfunction: diagnostic flow-chart could be simplified?]. Astegiano M, Cammarota T, Bresso F, Sapone N, Demarchi B, Bertolusso L, Sarno A, Bruno M, Pellicano R, Rizzetto M. *Minerva Gastroenterol Dietol.* 2001 Jun;47(2):53-60. Italian.
150. Decreasing eradication rate of Helicobacter pylori infection with metronidazole-based triple therapy. A randomised study. Pellicano R, Palmas F, Ponzetto A, Astegiano M, Smedile A, Morgando A, Bonardi R, Berrutti M, Touscoz GA, Rizzetto M. *Minerva Gastroenterol Dietol.* 2002 Sep;48(3):265-70.
151. A case of ulcerative jejunoileitis treated with anti tumor necrosis factor-alpha antibodies. Gaia S, Bruno M, Marzano A, Novero D, Astegiano M, Actis GC, Rizzetto M. *Panminerva Med.* 2005 Dec;47(4):269-72. No abstract available.
152. [Organisation of work teams at the gastroentero-hepatology outpatients clinic. The management of inflammatory bowel diseases]. Astegiano M, Bresso F, Demarchi B, Sapone N, Pellicano R, Palmas F, Rizzetto M. *Minerva Gastroenterol Dietol.* 2002 Mar;48(1):1-5. Italian. No abstract available.
153. The epidemiology of gastro-oesophageal reflux disease. A brief review. Pellicano R, Astegiano M, Rizzetto M. *Minerva Gastroenterol Dietol.* 2003 Dec;49(4):231-4.
154. How accurate is the culture of Helicobacter pylori in a clinical setting? An appraisal. Pellicano R, Smedile A, Ponzetto A, Berrutti M, Astegiano M, Saracco G, De Angelis C, Repici A, Morgando A, Abate ML, Fagoonee S, Rizzetto M. *Panminerva Med.* 2005 Sep;47(3):191-4.
155. Association between Crohn's disease and Conn's syndrome. A report of two cases. Astegiano M, Bresso F, Demarchi B, Sapone N, Novero D, Palestro G, Resegotti A, Pellicano R, Rizzetto M. *Panminerva Med.* 2005 Mar;47(1):61-4.

156. Autoimmune manifestations during interferon therapy in patients with chronic hepatitis C: the hepatologist's view. Pellicano R, Smedile A, Peyre S, Astegiano M, Saracco G, Bonardi R, Rizzetto M. *Minerva Gastroenterol Dietol*. 2005 Mar;51(1):55-61.
157. Side-to-side stapled anastomosis strongly reduces anastomotic leak rates in Crohn's disease surgery. Resegotti A, Astegiano M, Farina EC, Ciccone G, Avagnina G, Giustetto A, Campa D, Fronda GR. *Dis Colon Rectum*. 2005 Mar;48(3):464-8.
158. Laboratory evaluation of the patient with liver disease. Astegiano M, Sapone N, Demarchi B, Rossetti S, Bonardi R, Rizzetto M. *Eur Rev Med Pharmacol Sci*. 2004 Jan-Feb;8(1):3-9. Review.
159. Activity of Crohn disease: value of Color-Power-Doppler and contrast-enhanced ultrasonography. Robotti D, Cammarota T, Debani P, Sarno A, Astegiano M. *Abdom Imaging*. 2004 Nov-Dec;29(6):648-52. Epub 2004 May 27.
160. Analysis of the CARD15 variants R702W, G908R and L1007fs in Italian IBD patients. Giachino D, van Duist MM, Regazzoni S, Gregori D, Bardessono M, Salacone P, Scaglione N, Sostegni R, Sapone N, Bresso F, Sambataro A, Gaia E, Pera A, Astegiano M, De Marchi M. *Eur J Hum Genet*. 2004 Mar;12(3):206-12.
161. Detection of anti-Saccharomyces cerevisiae antibodies in Crohn's disease: is it a reliable diagnostic and prognostic marker? Sostegni R, Daperno M, Ercole E, Rigazio C, Bresso F, Masoero G, Castellino F, Zaffino C, Rocca R, Molinaro GC, Rocca G, Astegiano M, Pera A. *Dig Liver Dis*. 2001 Dec;33(9):755-61.
162. Clinical features in familial cases of Crohn's disease and ulcerative colitis in Italy: a GISC study. Italian Study Group for the Disease of Colon and Rectum. Annese V, Andreoli A, Astegiano M, Campieri M, Caprilli R, Cucchiara S, D'Inca R, Giaccari S, Iaquinto G, Lombardi G, Napolitano G, Pera A, Riegler G, Valpiani D, Andriulli A; Italian Study Group for the Disease of Colon and Rectum. *Am J Gastroenterol*. 2001 Oct;96(10):2939-45.
163. Safety and efficacy of azathioprine in the maintenance of ciclosporin-induced remission of ulcerative colitis. Actis GC, Bresso F, Astegiano M, Demarchi B, Sapone N, Boscaglia C, Rizzetto M. *Aliment Pharmacol Ther*. 2001 Sep;15(9):1307-11.
164. [Lithiasis of the gallbladder and biliary ducts: from epidemiology to therapy]. Pellicano R, Palmas F, Astegiano M, Vanni E, Leone N, Bresso F, Rizzetto M. *Minerva Med*. 2001 Aug;92(4):227-43. Review. Italian.
165. Abdominal pain and bowel dysfunction: diagnostic role of intestinal ultrasound. Astegiano M, Bresso F, Cammarota T, Sarno A, Robotti D, Demarchi B, Sostegni R, Macchiarella V, Pera A, Rizzetto M. *Eur J Gastroenterol Hepatol*. 2001 Aug;13(8):927-31.
166. [Gastroenterologists in ambulatory care. The experience in Turin in the year 2000]. Pellicano R, Ponzetto A, Astegiano M, Smedile A, Saracco G, Durazzo M, Balzola F, Berrutti M, Lavezzo B, Ponti V, Morgando A, Ciancio A, Rizzetto M, Palmas F. *Minerva Med*. 2001 Apr;92(2):79-83. Italian.
167. Screening for coeliac disease in women with recurrent spontaneous abortion sine causa. Pellicano R, Astegiano M, Fagoonee S, Rizzetto M. *Panminerva Med*. 2000 Dec;42(4):299-300. No abstract available.
168. [\[Abdominal pain and bowel dysfunction: the diagnostic role of ultrasonography\]](#). Cammarota T, Bresso F, Sarno A, Astegiano M, Macchiarella V, Robotti D. *Radiol Med*. 2000 Nov;100(5):337-42. Italian.
169. The relationship between heritability and smoking habits in Crohn's disease. Italian Cooperative Study Group. Brignola C, Belloli C, Ardizzone S, Astegiano M, Cottone M, Trallori G. *Am J Gastroenterol*. 2000 Nov;95(11):3171-5.
170. [Intestinal fistulas in Crohn disease]. Fronda GR, Resegotti A, Astegiano M, Farina EC, Patelli E, Giustetto A, De Paolis P. *Minerva Chir*. 2000 Jun;55(6):431-5. Italian.
171. Genotype-phenotype relationship in inflammatory bowel disease. Pera A, Sostegni R, Daperno M, Ercole E, Laudi C, Rocca R, Rigazio C, Astegiano M, Rocca G. *Eur J Intern Med*. 2000 Aug;11(4):204-209.
172. [Stricture plasty in Crohn's disease. Indications and results]. Resegotti A, Astegiano M, Sostegni R, Garino M, Fusi D, Longhin R. *Minerva Chir*. 2000 May;55(5):313-7. Italian.
173. The natural history of ulcerative proctitis: a multicenter, retrospective study. Gruppo di Studio per le Malattie Infiammatorie Intestinali (GSMII). Meucci G, Vecchi M, Astegiano M, Beretta L, Cesari P, Dizioli P, Ferraris L, Panelli MR, Prada A, Sostegni R, de Franchis R. *Am J Gastroenterol*. 2000 Feb;95(2):469-73.
174. Genetic analysis in Italian families with inflammatory bowel disease supports linkage to the IBD1 locus--a GISC study. Annese V, Latiano A, Bovio P, Forabosco P, Piepoli A, Lombardi G, Andreoli A, Astegiano M, Gionchetti P, Riegler G, Sturniolo GC, Clementi M, Rappaport E, Fortina P, Devoto M, Gasparini P, Andriulli A. *Eur J Hum Genet*. 1999 Jul;7(5):567-73.



175. Beclomethasone dipropionate enemas versus prednisolone sodium phosphate enemas in the treatment of distal ulcerative colitis. Campieri M, Cottone M, Miglio F, Manenti F, Astegiano M, D'Arienzo A, Manguso F, D'Albasio G, Bonanomi A, Galeazzi R, Orlando A, Castiglione GN, Gionchetti P. *Aliment Pharmacol Ther.* 1998 Apr;12(4):361-6.
176. Controlled trial of oral 5-aminosalicylic acid for the prevention of early relapse in Crohn's disease. de Franchis R, Omodei P, Ranzi T, Brignola C, Rocca R, Prada A, Pera A, Vecchi M, Del Piano M, Ferrara A, Belloli C, Piodi L, Framarin L, Astegiano M, Riccioli FA, Meucci G. *Aliment Pharmacol Ther.* 1997 Oct;11(5):845-52.
177. IgM antibody against measles virus in patients with inflammatory bowel disease: a marker of virus-related disease? Balzola FA, Castellino F, Colombatto P, Manzini P, Astegiano M, Verme G, Brunetto MR, Pera A, Bonino F. *Eur J Gastroenterol Hepatol.* 1997 Jul;9(7):661-3.
178. [Chronic diarrhea: a difficult diagnosis. A rare cause: lymphocytic colitis]. Pellicano R, Ponti V, Astegiano M, Pera A, Rizzetto M, Verme G. *Minerva Gastroenterol Dietol.* 1997 Mar;43(1):1-5. Italian.
179. Anti-neutrophil cytoplasmic antibodies in inflammatory bowel disease: do they recognize different subsets of a heterogeneous disease? Castellino F, Rosina F, Bansi DS, Bauducci M, Touscoz GA, Giorda L, Borghesio E, Bessone MP, Astegiano M, Musso A, et al. *Eur J Gastroenterol Hepatol.* 1995 Sep;7(9):859-64.
180. Clinical course of inflammatory bowel disease during treatment with interferon for associated chronic active hepatitis. Cottone M, Magliocco A, Trallori G, Brignola C, Vandelli C, Ardizzone S, Meucci G, Zannoni F, Di Maio G, Astegiano M. *Ital J Gastroenterol.* 1995 Jan-Feb;27(1):3-4.
181. [Instrumental diagnosis in chronic inflammatory intestinal diseases]. Barletti C, Rigazio C, Astegiano M, Bosio C, Cammarota T, Cacace G, Ponti V, Pera A. *Minerva Gastroenterol Dietol.* 1992 Apr-Jun;38(2):71-9. Review. Italian. No abstract available.
182. Antibodies to Mycobacterium paratuberculosis in patients with Crohn's disease. Brunello F, Pera A, Martini S, Marino L, Astegiano M, Barletti C, Gastaldi P, Verme G, Emanuelli G. *Dig Dis Sci.* 1991 Dec;36(12):1741-5.
183. [Intestinal ischemia: nosographic framework and risk factors]. Andriulli A, Pera A, Gindro T, Astegiano M, Verme G. *Minerva Med.* 1990 Jan-Feb;81(1-2):55-60. Italian.
184. Ultrasonography in the detection of Crohn's disease and in the differential diagnosis of inflammatory bowel disease. Pera A, Cammarota T, Comino E, Caldera D, Ponti V, Astegiano M, Barletti C, Rocca R, Cosimato M, Bertolusso L. *Digestion.* 1988;41(3):180-4.
185. Colonoscopy in inflammatory bowel disease. Diagnostic accuracy and proposal of an endoscopic score. Pera A, Bellando P, Caldera D, Ponti V, Astegiano M, Barletti C, David E, Arrigoni A, Rocca G, Verme G. *Gastroenterology.* 1987 Jan;92(1):181-5.
186. [Echotomography in the diagnosis of Crohn's disease]. Cammarota T, Pera A, Bellando P, Astegiano M, Comino E. *Radiol Med.* 1985 Sep;71(9):597-601. Italian.

Il sottoscritto dichiara di essere stato informato che i dati personali contenuti nel presente documento, trattati ai fini della realizzazione di progetti ed eventi ECM, saranno inoltrati agli Organi competenti in materia di Educazione Continua in Medicina e pubblicati sul sito web di riferimento per l'ECM.

Il sottoscritto autorizza la pubblicazione del presente Curriculum Vitae e il trattamento dati personali contenuti nello stesso ai sensi del D.L. 196/2003 – Codice in materia di protezione dei dati personali.

La firma in calce dichiara il proprio consenso sia alla pubblicazione che al trattamento di cui sopra.

Dott. Marco Astegiano



Torino, \_\_\_\_\_ 31/07/2023 \_\_\_\_\_

